Clinical trials: Protein
Plasma Cell Myeloma
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
Primary Objective: Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed/refractory multiple myeloma (RRMM).
- Trial name
- NCT02514668
- Testing
- Isatuximab
- Where
- 18 sites in United States, Czechia and 1 more
- Volunteers
- 55 people
- Sponsor
- Sanofi
Multiple Myeloma
A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
The purpose of this study is to evaluate the pharmacokinetic (PK-the study of the way a drug enters and leaves the blood and tissues over time) characteristics of bortezomib when administered intravenously in Taiwanese…
- Trial name
- NCT02268890
- Testing
- Bortezomib
- Where
- 6 sites in Taiwan
- Volunteers
- 18 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Advanced Solid Tumors With MAPK Pathway Mutations
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with…
- Trial name
- NCT05886920
- Testing
- D3S-002, D3S-001
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 67 people
- Sponsor
- D3 Bio (Wuxi) Co., Ltd
Multiple Myeloma
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Multiple myeloma is the second most common hematologic malignancy in adults and despite the new therapies that have been developed in the last decades it remains incurable.
- Trial name
- MARINA (NCT07559799)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- iOMEDICO AG
Healthy Adults
Effects of a Single Oral Dose of Sweet Protein Sweelin® on Blood Glucose and Insulin Levels in Healthy Adults
The study aims to evaluate, for the first time, the post-prandial effects of a single oral administration of Serendipity Berry Sweet Protein sweelin® compared to glucose and stevia, as a commercial sweetener, in healthy adults.
- Trial name
- NCT06520293
- Testing
- Sweet Beverage
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amai Proteins
Pancreatic Cancer, Pancreatic Cancer Metastatic
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- MAPKeeper 301 (NCT07562152)
- Testing
- Atebimetinib, GnP, mGnP
- Where
- 70 sites in United States, Australia and 7 more
- Volunteers
- 510 people
- Sponsor
- Immuneering Corporation
Multiple Myeloma
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 with Daratumumab Injection in Healthy Chinese Male Subjects
- Trial name
- NCT05679258
- Testing
- HLX15, US-sourced DARZALEX®, CN-sourced DARZALEX®
- Where
- 2 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Hemophilia B
Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B
To assess efficacy and safety of BeneFix® for prophylaxis in "Short-term" therapy and on demand therapy for all bleeding episodes of subjects with hemophilia B.
- Trial name
- NCT00581126
- Testing
- Recombinant Factor IX Coagulation
- Volunteers
- 14 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Multiple Myeloma
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who…
- Trial name
- KarMMa-2 (NCT03601078)
- Testing
- bb2121, Lenalomide, Talquetamab
- Where
- 25 sites in United States, France and 4 more
- Volunteers
- 312 people
- Sponsor
- Celgene
Uveal Melanoma
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic…
- Trial name
- NCT02601378
- Testing
- LXS196, LXS196 and HDM201
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT00511238
- Testing
- carfilzomib
- Where
- 34 sites in United States, Canada
- Volunteers
- 312 people
- Sponsor
- Amgen
Multiple Myeloma
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
The purpose of this study is to evaluate the safety and effect on the body of Tabalumab (LY2127399) in combination with bortezomib and dexamethasone in Japanese participants with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT01556438
- Testing
- Tabalumab, Bortezomib IV, Bortezomib SC
- Where
- 5 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
COVID - 19
PA-001 Ph.1 Study in Healthy and Elderly Subjects
This was a double blind, randomized, placebo controlled, single and multiple IV dose study conducted in 2 parts, single ascending dose and multiple ascending doses parts.
- Trial name
- NCT07518771
- Testing
- PA-001
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- PeptiDream Inc.
Healthy Volunteers
Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein single dose in Chinese healthy volunteers.
- Trial name
- NCT01901198
- Testing
- Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C., Peginterferon 180 mcg single dose S.C.
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Beijing Bio-Fortune Ltd.
Hemophilia A
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A
The primary objective of the study is to evaluate the safety of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in previously treated pediatric subjects with hemophilia A.
- Trial name
- Kids ALONG (NCT01458106)
- Testing
- BIIB031 (rFVIIIFc), FVIII (PK subgroup only)
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 71 people
- Sponsor
- Bioverativ Therapeutics Inc.
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03844048
- Testing
- Venetoclax
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- AbbVie
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
Advanced Cancer, Gastric Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- Minnelide 101 (NCT03129139)
- Testing
- Minnelide™Capsules
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Minneamrita Therapeutics LLC
Hemophilia A
Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis
This NIS aims to assess the patient-reported outcomes (PROs) in enrolled subjects
- Trial name
- NCT02718677
- Testing
- Refacto AF
- Sponsor
- Pfizer
Glioma of Brain
A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.
- Trial name
- NCT03650257
- Testing
- gp96, Temozolomide, radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Cure&Sure Biotech Co., LTD